Press Releases

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe "Mori" Arkin to Its Board of Directors

Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash

Lutris Pharma Announces Publication of Positive Data From Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer

Lutris Pharma Presents Data From a Real-World Analysis of Skin Toxicity From EGFR Inhibitors - an Unmet Challenge, at the 2023 American Academy of Dermatology Annual Meeting

Lutris Pharma to Present at the 16th Annual European Life Sciences CEO Forum in March

Lutris Pharma's Founder and Chairman of the Board Receives $5.0 Million Grant from the California Institute of Regenerative Medicine (CIRM) to Develop LUT017 for Wound Healing

Lutris Pharma Receives Notice of Allowance for Patent Covering the Use of B-Raf Inhibitors in MEK Inhibitor induced rash

Lutris Pharma Reports Positive Top-Line Results From the Open Label Part 1 and Double Blinded Part 2 of Its Phase 1/2 Trial of LUT014 to Treat Radiation Dermatitis in Patients with Breast Cancer

Lutris Pharma Appoints Company Founder, Antoni Ribas, M.D., Ph.D., as Chairman of the Board of Directors

Lutris Pharma to Present at the Bio€quity Europe Conference

Lutris Pharma Completes Enrollment of Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Patients with Breast Cancer

Lutris Pharma to Participate in Virtual Investor Conferences in January

Lutris Pharma Expands Intellectual Property Portfolio Surrounding its Novel B-Raf inhibitors Including Lead Asset LUT014

Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients

Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014 -- a Topical Gel for the Reduction of Dose-Limiting Acneiform Lesions -- in Metastatic Colorectal Cancer Patients Treated with EGFR Inhibitor Therapy

Lutris Pharma Appoints Life Science Executive, Jack Weinstein, as Chairman of the Board of Directors

Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery

Topical therapy can help safely reduce side effect of cancer treatment

Novel BRAF-Inhibitor Cream Ameliorates Rash From EGFR Inhibitors

Side effect of cancer treatment can be safely reduced with topical cream

Israel’s Lutris shares positive readout from early-stage trials of B-Raf inhibitor